Purchase this article with an account.
Jose Lorenzo Carrero, Alexandros Deligiannidis; Systemic adverse events after antiangiogenic therapy in clinical trials comparing Bevacizumab and Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2013;54(15):249. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To examine and compare the evidence of incidental severe systemic adverse events one year after antiangiogenic therapy with Ranibizumab and Bevacizumab.
We searched CENTRAL, MEDLINE, EMBASE. There were no date or language restrictions in the electronic searches for trials. We included all randomised controlled trials (RCTs) comparing bevacizumab and ranibizumab. we examine the ocurrence of systemic serious adverse events. We pooled data using a fixed-effect model.
We included three RCTs in this review. Overall the quality of the evidence was high. There were 1795 treated patients; 882 with bevacizumab, and 913 with ranibicizumab. The pooled risk difference for systemic adverse events was 0.001 (p=0.265). An analysis by specific event showed that the risk difference for gastrointestinal disorders was 0.017 more frequent in patients undergoing bevacizumab treatment (p=0.003).
Though reviewed RCTs were not specifically designed to detect any difference in adverse outcomes, pooled data show that both treatments are comparably safe, except for differences found in the ocurrence of Gastrointestinal disorders which could be related to the baseline differences in medical conditions of participants.
This PDF is available to Subscribers Only